Oruka Therapeutics (ORKA) vs PTC Therapeutics (PTCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Oruka Therapeutics (ORKA) has outperformed PTC Therapeutics (PTCT) over the past year, gaining 221.4% versus a loss of 2.0%. Over five years, ORKA leads with a +145.3% price change compared with +69.9% for PTCT. Oruka Therapeutics is the larger company by market cap ($5.44 billion vs $5.40 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ORKA | PTCT |
|---|---|---|
| Share price | $82.11 | $64.70 |
| Market cap | $5.44B | $5.40B |
| 1-day change | +6.25% | +3.42% |
| YTD return | +170.90% | -14.82% |
| 1-year return | +221.37% | -1.98% |
| 5-year return | +145.25% | +69.86% |
| Forward P/E | — | 27.30 |
| EPS (TTM) | $-2.04 | $-0.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.73B |
| Revenue growth (YoY) | — | +114.51% |
| Net income (latest FY) | $-105.43M | $682.64M |
| Operating margin | — | 50.09% |
| Net margin | — | 39.44% |
| 52-week high | $115.52 | $90.87 |
| 52-week low | $24.46 | $61.23 |
| Distance from 52-week high | -28.92% | -28.80% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +88.77% | +56.21% |
| Average volume | 902.84K | 1.14M |
| Shares outstanding | 66.21M | 83.46M |
| Employees | 68 | 991 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ORKA has outperformed PTCT by 223.4 percentage points over the past year.
About Oruka Therapeutics
ORKA stock →Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions.
Healthcare · Biotechnology · 68 employees
About PTC Therapeutics
PTCT stock →PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.
Healthcare · Biotechnology · 991 employees
ORKA vs PTCT FAQ
Which is bigger, Oruka Therapeutics or PTC Therapeutics?
Oruka Therapeutics (ORKA) is larger, with a market capitalization of $5.44B compared with $5.40B for PTC Therapeutics (PTCT).
Which stock has performed better over the past year, ORKA or PTCT?
ORKA returned +221.37% over the past 12 months, compared with -1.98% for PTCT (price return, excluding dividends). Past performance does not predict future results.
Are Oruka Therapeutics and PTC Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.